Project Grant R01AR087168
Award Date 8/15/26
Completion Date 7/31/30
Dollars Obligated $3.7M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded Wake Forest University Health Sciences $426,250 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate sensory neuron-fibroblast crosstalk in knee osteoarthritis. The research examines how sensory neuron-derived calcitonin gene-related peptide (CGRP) regulates inflammation and fibrosis within joint tissue, contributing to osteoarthritis pain and disease progression. The work focuses...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $1,054,899 on September 19, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to conduct research on JAK-specific signaling in post-traumatic osteoarthritis-associated joint degeneration and pain. Duke University's Office of Research Administration will identify which Janus kinases (JAK1, JAK2, and/or TYK2) mediate both cartilage catabolism and nociceptive...
- The National Institute of Neurological Disorders and Stroke awarded the University of Pittsburgh $9.799 million on September 19, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to elucidate biopsychosocial mechanisms underlying inter-individual differences in movement-evoked pain and functional impairment in knee osteoarthritis. The research uses concurrent ambulatory brain imaging and gait biomechanics during the 6-minute walk test to identify overlapping and distinct...
- This Project Grant award of $2,068,842 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify how pain influences the activity of prefrontal cortical dynorphin neurons and their role in modulating nociception and maladaptive affective behaviors. The research aims to dissect the mechanisms by which dynorphin neurons and release of dynorphin neuropeptides or fast neurotransmitters...
- The University of Miami is conducting a research project under a $1,109,446 Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH). The project, funded through the Drug Abuse and Addiction Research Programs (CFDA 93.279), aims to develop a novel non-opioid analgesic based on gene therapy targeting the carbonic anhydrase-8 (CA8) protein to treat chronic pain associated with knee osteoarthritis. The...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Ohio University $665,615 on August 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of a novel SIRT5 allele in osteoarthritis development. The research examines how altered SIRT5 activity in chondrocytes disrupts cellular metabolism and joint inflammation to increase osteoarthritis susceptibility. The recipient will conduct studies on a rare...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Connecticut Health Center $658,289 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a minimally invasive periarticular injection therapy for managing knee osteoarthritis pain. The project will engineer a combination treatment comprising local anesthetics and a pain modulator delivered via periarticular injection—rather than...
- The National Institute of Neurological Disorders and Stroke awarded a cooperative agreement worth $4,041,667 to Cincinnati Children's Hospital Medical Center on September 19, 2025, to conduct research on the biopsychosocial determinants of pediatric-onset chronic musculoskeletal pain. The research employs a mixed retrospective-prospective cohort study design to enroll 600 adolescents and young adults ages 16–26, including 400 with primary chronic musculoskeletal pain or chronic musculoskeletal...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Northeastern University $652,195 on June 17, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and test surface-modified, cartilage-targeting exosomes as non-viral gene delivery vehicles for osteoarthritis treatment. The project engineers charge-reversed cationic exosomes derived from mesenchymal stem cells, anchored with arginine-rich peptide motifs, to...